EN DE
Watch Cyclerion Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Cyclerion Therapeutics Inc (CYCN) fair value: what the stock is really worth

As of Oct 14, 2026: fair value (intrinsic value) of Cyclerion Therapeutics Inc stock $5.58, price $3.36, upside +66.1%, quality 51 out of 100. Rating: strongly undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

CT Cyclerion Therapeutics Inc logo Thin data Nov 7, 2026

Cyclerion Therapeutics Inc

CYCN · US
Meets all rules

The stock costs 40% less than our calculation considers fair.

Fair value $5.58 · Strongly undervalued
Low debt
Even on cautious assumptions the value is 10% above the price ($3.69).
Quality 51/100
Mixed vs. peers (5/9)
Weak Growth (revenue 5y −2.0 %/yr in USD)
Loss-making · -170.1% net margin (FY2025)
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Watch Cyclerion Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$6.35 $0.1912 Fair Value $5.58 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $0.1912 – $6.35 · fair‑value band $3.69 – $6.98 · the $3.36 price screens below the $5.58 fair value. As of Nov 7, 2026.

Follow Cyclerion Therapeutics in your weekly email

Every Wednesday you see whether Cyclerion Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery.

Show moreShow less

The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease.

It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Stock analysis

Cyclerion Therapeutics Inc (CYCN) currently trades at $3.36, while our model-based Fair Value estimate is $5.58, implying the stock looks roughly 40% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $3.69 (bear) to $6.98 (bull), the price of $3.36 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Cyclerion Therapeutics Inc reported revenue of $2.1M in FY2025 versus $3.3M in FY2021, a compound −11.1%/yr. Reported net income was −$3.5M in FY2025.

Key figures

Market cap $2.2M Micro · P/S ratio 1.18 · EPS (TTM) $−11.62 · Return on equity −98.2% · Return on assets (EBIT) −76.0% (5-year average) · Operating margin −359% · Revenue (TTM) $1.9M · Revenue growth (YoY) −43.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 211% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 66%, CYCN screens cheaper than that median.

Fair Value models

Bear $3.69 Fair Value $5.58 Bull $6.98
Price $3.36 · Upside +66.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $3.69 $5.58 $6.98 54
All 1 models by family
Asset-Based
NCAV (Graham) $3.69 $5.58 $6.98 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 51/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 29
Are margins and returns getting better?
Cashflow 32
Do the profits arrive as real cash?
Financial strength 70
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 2
How calm the share price moves, does not count
Price momentum 81
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 3 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+3.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+91.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−3,539.4% (2020) → −239.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch CYCN, get fair value alerts →

Compare Cyclerion Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 4/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 51 · Above median
Fair Value upside +66.1% · Top 25%
Profitability
Return on assets −35.3% · Below median
Net margin (12 months) −170.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −43.2% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.25× · Cheapest 25%
P/S (12 months) 1.18× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 22

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs CYCN
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs CYCN
Samsung Biologics Co 207940 1,510,000 KRW 1,667,600 KRW +10% vs CYCN
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs CYCN
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs CYCN
WuXi Biologics (Cayman) Inc 2269 HK$48.92 HK$52.38 +7% vs CYCN
argenx SE ARGX $927.21 $908.40 −2% vs CYCN
CSL Limited CSL A$200.77 A$183.04 −9% vs CYCN
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs CYCN
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs CYCN

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cyclerion Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Cyclerion Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/CYCN

Frequently asked questions

Is Cyclerion Therapeutics Inc (CYCN) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $5.58 versus the last price from Oct 14, 2026 of $3.36, about +66% upside (undervalued).
What is the fair value of CYCN?
Our model-based fair value for Cyclerion Therapeutics Inc is $5.58 (as of Nov 7, 2026), built from audited fundamentals. Last price (from Oct 14, 2026): $3.36.
What is the quality score of CYCN?
Cyclerion Therapeutics Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cyclerion Therapeutics Inc (CYCN)?
Our model-based price target is the fair value of $5.58 (as of Nov 7, 2026) from 1 valuation models. Cautious scenario $3.69, optimistic scenario $6.98. It is a calculation from audited fundamentals, not an analyst target.
What is the Cyclerion Therapeutics Inc stock forecast for 2026?
Our models put fair value at $5.58, about +66% upside versus the last price from Oct 14, 2026 of $3.36 (undervalued). Cautious scenario $3.69, optimistic scenario $6.98. The calculation is refreshed regularly with new filings.
What is the revenue of Cyclerion Therapeutics Inc (CYCN)?
Cyclerion Therapeutics Inc reported trailing-twelve-month revenue of about $1.9M (latest available figure, as of Nov 7, 2026).
What is the intrinsic value of Cyclerion Therapeutics Inc (CYCN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cyclerion Therapeutics Inc it is $5.58 per share (as of Nov 7, 2026), against a price of $3.36. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Cyclerion Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, CYCN trades below its calculated fair value: price $3.36, fair value $5.58, a gap of about +66% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CYCN?
No. The price is what the market pays today ($3.36); the fair value is what the company's own numbers justify ($5.58). For Cyclerion Therapeutics Inc the two are $2.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cyclerion Therapeutics Inc worth?
The market values Cyclerion Therapeutics Inc at about $2.2M (market capitalisation, as of Nov 7, 2026). Per share that is $3.36; our models calculate a fair value of $5.58 per share.
What do the bullish and bearish scenarios say about CYCN?
Our models span a range for Cyclerion Therapeutics Inc: cautious scenario $3.69, base $5.58, optimistic $6.98 per share (as of Nov 7, 2026, price $3.36). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cyclerion Therapeutics Inc (CYCN)?
Balance-sheet figures for Cyclerion Therapeutics Inc (as of Nov 7, 2026): return on equity −98.2%. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is CYCN from its 52-week high?
Cyclerion Therapeutics Inc trades at $3.36, about 26% below its 52-week high of $4.52 and 211% above the low of $1.08 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of $5.58 is for.
Which stocks are comparable to Cyclerion Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cyclerion Therapeutics Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $3.36, calculated fair value $5.58 (+66%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CYCN calculated?
We run Cyclerion Therapeutics Inc through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $5.58 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Cyclerion Therapeutics Inc currently trades 40% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cyclerion Therapeutics Inc (CYCN)?
The latest price we hold is from Oct 14, 2026 and stands at $3.36. Our model-based fair value is $5.58, about +66% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cyclerion Therapeutics Inc right now?
The price is below even our cautious bear case ($3.69). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($3.69 to $6.98) leaves room in how you read the outcome.

Key figures of Cyclerion Therapeutics Inc

How large is the market capitalisation of Cyclerion Therapeutics Inc (CYCN)?
The market capitalisation of Cyclerion Therapeutics Inc is $2.2M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cyclerion Therapeutics Inc (CYCN)?
The price-to-sales ratio of Cyclerion Therapeutics Inc is 1.18 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cyclerion Therapeutics Inc (CYCN)?
Earnings per share at Cyclerion Therapeutics Inc are $−11.62. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cyclerion Therapeutics Inc (CYCN)?
The return on equity (ROE) of Cyclerion Therapeutics Inc is −98.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cyclerion Therapeutics Inc (CYCN)?
On an EBIT basis the return on assets of Cyclerion Therapeutics Inc is −76.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cyclerion Therapeutics Inc (CYCN)?
The operating margin of Cyclerion Therapeutics Inc is −359% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cyclerion Therapeutics Inc (CYCN)?
Revenue at Cyclerion Therapeutics Inc is growing −43.2% versus a year earlier (3y avg +91.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cyclerion Therapeutics Inc (CYCN) generate?
The free cash flow of Cyclerion Therapeutics Inc is −$3.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Cyclerion Therapeutics Inc (CYCN) hold?
Cyclerion Therapeutics Inc holds more cash than debt, $3.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Cyclerion Therapeutics Inc in the live analysis

One click puts Cyclerion Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.